Illumina stock is trading -23.87% below its average target price of $162.32 after dropping -5.7% during today's afternoon session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $120.0 to $250.0 per share.
The stock has an average amount of shares sold short at 4.3%, and a short ratio of 2.72. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 107.6% of Illumina's shares being owned by this investor type.
Institutions Invested in Illumina
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 12% | 18,546,274 | $2,291,948,574 |
| 2024-09-30 | Vanguard Group Inc | 10% | 15,914,200 | $1,966,676,865 |
| 2024-09-30 | State Street Corporation | 4% | 5,607,824 | $693,014,900 |
| 2024-09-30 | Loomis Sayles & Company, LP | 3% | 4,342,740 | $536,675,817 |
| 2024-12-31 | WCM Investment Management, LLC | 3% | 4,129,855 | $510,367,488 |
| 2024-09-30 | Capital World Investors | 2% | 3,544,069 | $437,976,053 |
| 2024-09-30 | Bank Of New York Mellon Corporation | 2% | 3,374,439 | $417,013,177 |
| 2024-12-31 | Baillie Gifford and Company | 2% | 3,018,193 | $372,988,296 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 2,727,827 | $337,104,865 |
| 2024-09-30 | Guardcap Asset Management Ltd. | 2% | 2,724,818 | $336,733,013 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Illumina.
